About this trial
Anxiety and depressive symptoms are prevalent in patients undergoing surgical repair for ureteral stricture, driven by chronic pain, renal function concerns, and surgical uncertainty. Dexmedetomidine has anxiolytic and antidepressant effects but may increase bradycardia and hypotension; esketamine provides rapid antidepressant efficacy but may cause psychiatric side effects. Preliminary studies showed that combined use of low-dose dexmedetomidine and esketamine reduced the prevalence of postoperative depressive symptoms without increasing adverse events. This study is designed to test the hypothesis that perioperative use of low-dose dexmedetomidine-esketamine combination may relieve postoperative depressive symptoms and anxiety in patients undergoing laparoscopic ureteral reconstruction.
Eligibility criteria
Qualifiers
Aged ≥ 18 years;
Diagnosed with ureteral stricture and scheduled for elective laparoscopic ureteral reconstruction under general anesthesia;
Requiring patient-controlled intravenous analgesia after surgery.
Disqualifiers
Preoperative inability to communicate due to coma, delirium, severe dementia, or language barrier;
History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;
Presence of preexisting left ventricular ejection fraction (LVEF) < 30%, sick sinus syndrome, severe sinus bradycardia (heart rate < 50 beats/min), or atrioventricular block above grade II without pacemaker implanted;
Uncontrolled hyperthyroidism or history of pheochromocytoma;
Trial design
Treatments tested in this trial
- Combined dexmedetomidine-esketamine administration
- Placebo administration